Forte Biosciences (FBRX) Tax Provisions (2018 - 2026)

Forte Biosciences (FBRX) reported Tax Provisions of $373000.0 for Q1 2026, up 97.35% quarter-over-quarter from $189000.0 in Q4 2018.

Forte Biosciences (FBRX) Tax Provisions (2018 - 2026) Analysis & Trends

Forte Biosciences (FBRX) has 2 years of Tax Provisions data on file, last reported at $373000.0 in Q1 2026.

Tax Provisions for Q1 2026 came in at $373000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $562000.0 (down 66.9% YoY), and the FY2025 annual result was $1.0 million, changed N/A from the prior year.
Tax Provisions grew to $373000.0 in Q1 2026 per FBRX's latest filing, from $189000.0 in the prior quarter.
Over five years, Tax Provisions peaked at $373000.0 in Q1 2026 and troughed at $373000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-11.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	216,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-859,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	221.50 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Forte Biosciences	70.77 Mn	12.55 Mn	-	373,000.00

Download Data